Abstract
Histoplasmosis results from infection with the fungal organism Histoplasma capsulatum. Most Histoplasma research today uses models based on primary pulmonary infection. Following inhalation, conidia are rapidly ingested and intracellularly convert to the yeast form. After initial pulmonary infection, organisms are carried throughout the body giving rise to disseminated infection. Three murine infection models have been developed which mimic human disease. These comprise models of primary infection following initial exposure to the organism, secondary exposure to Histoplasma following spontaneous recovery from primary disease and a model of reactivated infection following spontaneous clearance of primary disease. This chapter describes these models and explores variability introduced with the use of mice of varied genetic backgrounds and different H. capsulatum strains.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kauffman CA. (2007) Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 20:115–32.
Chick EW and Roberts GD. (1974) The varying susceptibility of different genetic strains of laboratory mice to Histoplasma capsulatum. Mycopathol Mycol Appl. 52:251–3.
Deepe GS. (1993) Histoplasma capsulatum and V beta a mice: cellular immune responses and susceptibility patterns. J Med Vet Mycol. 31:181–8.
Nosanchuk JD and Gacser A. (2008) Histoplasma capsulatum at the host-pathogen interface. Microbes Infect. 10:973–7.
Haynes RR, Connolly PA, Durkin MM, et al. (2002) Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis. 185:1830–2.
Deepe GS Jr, and Gibbons RS. (2006) T cells require tumor necrosis factor-alpha to provide protective immunity in mice infected with Histoplasma capsulatum. J Infect Dis. 193:322–30.
Allen HL and Deepe GS Jr. (2006) B cells and CD4-CD8- T cells are key regulators of the severity of reactivation histoplasmosis. J Immunol. 177:1763–71.
U.S. Department of Health and Human Services Dept., Public Health Service, National Institutes Health, and Centers for Disease Control and Prevention. (2009) Biosafety in Microbiological and Biomedical Laboratories. 5th edition U.DS. Government Priniting Office, Washington D.C.
Retallack DM and Woods JP. (1999) Molecular epidemiology, pathogenesis, and genetics of the dimorphic fungus Histoplasma capsulatum. Microbes Infect. 1:817–25.
Magrini V and Goldman WE. (2001) Molecular mycology: a genetic toolbox for Histoplasma capsulatum. Trends Microbiol. 9:541–6.
Patton RM, Riggs AR, Compton SB and Chick EW. (1976) Histoplasmosis in purebred mice: influence of genetic susceptibility and immune depression on treatment. Mycopathologia. 60:39–43.
Mayfield JA and Rine J. (2007) The genetic basis of variation in susceptibility to infection with Histoplasma capsulatum in the mouse. Genes Immun. 8:468–74.
Deepe GS Jr, Romani L, Calich VL et al. (2000) Knockout mice as experimental models of virulence. Med Mycol. 38 Suppl 1:87–98.
Deepe GS Jr. (2007) Tumor necrosis factor-alpha and host resistance to the pathogenic fungus, Histoplasma capsulatum. J Investig Dermatol Symp Proc. 12:34–7.
Allendoerfer R and Deepe GS Jr. (1997) Intrapulmonary response to Histoplasma capsulatum in gamma interferon knockout mice. Infect Immun. 65:2564–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Smulian, A.G. (2012). Invasive Models of Histoplasmosis. In: Brand, A., MacCallum, D. (eds) Host-Fungus Interactions. Methods in Molecular Biology, vol 845. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-61779-539-8_37
Download citation
DOI: https://doi.org/10.1007/978-1-61779-539-8_37
Published:
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-61779-538-1
Online ISBN: 978-1-61779-539-8
eBook Packages: Springer Protocols